RAD.ASX: RAD Announces Positive Phase 2b Trial Results of RAD 101

RAD Announces Positive Phase 2b Trial Results of RAD 101

Stock	Radiopharm Theranostics Ltd (RAD.ASX)
Release Time	22 Jul 2026, 8:22 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

RAD Announces Positive Phase 2b Trial Results of RAD 101

Key Points

RAD 101 PET demonstrated 93% concordance with MRI in brain metastases diagnosis
Preliminary data shows 86% sensitivity in detecting brain metastases
Plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

Full Summary

Radiopharm Theranostics announced positive results from the Phase 2b trial of RAD 101, a novel imaging agent targeting fatty acid synthase (FASN) for diagnosing brain metastases. The trial showed 93% concordance between PET imaging and MRI in diagnosing brain metastases, meeting the primary endpoint. Preliminary data from 14 patients showed 86% sensitivity, indicating RAD 101's potential to accurately identify brain metastases. The company plans to advance RAD 101 into a U.S. Phase 3 pivotal trial in Q4 2026. RAD 101 has received FDA Fast Track Designation and a partnership with Siemens Healthineers for manufacturing and distribution.

Outlook

The positive trial results provide a strong foundation for the upcoming pivotal trial, with the potential to bring a more precise diagnostic tool to patients and clinicians.